Clinical trial · Interventional
Sildenafil Citrate in Waldenstrom's Macroglobulinemia
Phase II Study of Sildenafil Citrate in Waldenstrom's Macroglobulinemia
NCT00165295CI-TRIAL-00005098completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the effects (good or bad) that sildenafil (Viagra) has on patients with slow growing Waldenstrom's macroglobulinemia (WM). Sildenafil blocks the function of several proteins necessary to the survival of certain types of cancer and laboratory tests have shown that it can destroy WM cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Waldenstrom's Macroglobulinemia | Waldenstrom Macroglobulinemia | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sildenafil citrate (Viagra) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To determine response, time to progression and safety for sildenafil citrate therapy in patients with slowly progressing Waldenstrom's macroglobulinemia.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinicopathological diagnosis of Waldenstrom's macroglobulinemia * Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level of \> 2 times the upper limit of each institution's normal value * Slowly progressing disease not requiring therapy for at least 3-6 months * ECOG performance status 0,1 or 2 * Total bilirubin \< 2 x ULN * SGOT \< 3 x ULN * Creatinine \< 2 x ULN Exclusion Criteria: * Pregnant or breast-feeding women * Patients who are using organic nitrates or alpha-blockers * Grade III/IV cardiac problems * Resting hypotension (BP \< 90/50) or hypertension (BP \> 170/110) * Cardiac failure or coronary artery disease causing unstable angina * Evidence of left ventricular outflow obstruction * Impaired autonomic control of blood pressure * Sickle cell anemia * History of priapism * Severe and/or uncontrolled medical disease * Known chronic liver disease * Currently using ritonavir * History of retinal pigmentosa
References
Publications (0)
Data not yet available
No reference posted for this study.